Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

PhaseRX shares surge as it halves workforce to cut costs

PhaseRx said its restructuring was aimed at preserving its cash resources
health
PhaseRx will delay the development of its lead product candidate

PhaseRx Inc. NASDAQ:PZRX) shares rocketed up more than 80% after the biopharmaceutical company announced it was cutting 10 jobs, representing half of its workforce.

The job cuts include some executive officers as part of a corporate restructuring, which PhaseRx said was aimed at preserving cash resources.

The firm had cash and equivalents of US$8.4mln and a total of 20 employees on 30 June.

PhaseRx also said it would delay the development of its lead product candidate PRX-OTC , a treatment for children with inherited enzyme deficiencies in the liver,

Shares jumped 80.78% to 1.60p each in early US trading, marking a major rebound after falling 43%  in the year to date though Thursday. 

View full PZRX profile View Profile

Related Articles

Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use